2023

In comparing the period between 2007 and 2012 with 2018 and 2019, systemic therapy cost increased sixfold to ninefold.

During a Targeted Oncology™ Case-Based Roundtable™ event, April K.S. Salama, MD, and other physicians discussed which patients are more challenging when it comes to tolerating dual immunotherapy as frontline therapy for metastatic melanoma.

Inderjit Mehmi, MD, medical oncologist, Cedars-Sinai The Angeles Clinic and Research Institute, discusses the rationale for investigating the combination of fianlimab (REGN3767) and cemiplimab (Libtayo) in patients who have advanced melanoma with poor-risk features.

When Susanne Gabrielsson first learned about exosomes, her eyes widened. In 1999, she’d just started a postdoctoral fellowship at the Curie Institute in Paris.